Key result
A prior history of stroke independently increased the risk of stroke or systemic embolism (HR 3.4) in Japanese patients with non-valvular atrial fibrillation receiving rivaroxaban.
Why the study?
Risk factors for embolism and major bleeding under DOACs may differ from current reports, prompting evaluation in Japanese NVAF patients in the direct oral anticoagulant era.
Population
7141 Japanese NVAF patients receiving rivaroxaban
Design
Study sub-analysis
Authors
Loading...
May suggest differing embolism and bleeding risks in Japanese NVAF on DOACs; leaves open score recalibration for this population.
Cohort (n=7,141)
Yes
Hazard Ratio: 3.4 (95% CI 2.5–4.7)
Absolute Event Rate: 2.3% vs 0.7%
p-value: p=<0.0001
In Japanese patients with non-valvular atrial fibrillation treated with rivaroxaban, history of stroke strongly predicts stroke/systemic embolism, while moderate renal impairment and other HAS-BLED components predict major bleeding.
Sakuma et al. (2019) conducted a cohort in Non-valvular atrial fibrillation (n=7,141). History of stroke vs. No history of stroke was evaluated on Stroke or systemic embolism (HR 3.4, 95% CI 2.5-4.7, p=<0.0001). A prior history of stroke independently increased the risk of stroke or systemic embolism (HR 3.4) in Japanese patients with non-valvular atrial fibrillation receiving rivaroxaban.